Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

French President Emmanuel Macron visits a hospital near Paris. Photo: Yoan Valat/AFP via Getty

Long-awaited data from the Oxford/AstraZeneca U.S. trial suggests the vaccine is safe, 79% effective at preventing symptomatic COVID-19, and fully effective at preventing hospitalizations and deaths.

Yes, but: The suspension of the vaccine in at least 13 countries due to blood-clotting concerns has severely damaged the shot’s reputation in Europe, with majorities in France (61%), Germany (55%) and elsewhere now deeming it unsafe, according to a YouGov poll.

Driving the news: The rollout has resumed in most of Europe (Nordic countries are holding off), but it’s unclear how successful it can be when so few people appear prepared to take it.

  • It could be even more damaging if that lack of faith spreads to developing countries, where AstraZeneca's vaccine is the most widely available option.

The state of play: Leaders in Brussels are currently more worried about supply than demand. They’re considering blocking some exports to the U.K. on the grounds that the U.K. is importing doses produced on the continent but not reciprocating.

  • U.K. Prime Minister Boris Johnson is lobbying his EU counterparts against a potential ban, and Pfizer has warned that banning exports could weaken supply chains.

Between the lines: The U.K. signed a contract with AstraZeneca that called for doses produced in Britain to stay there, much as the U.S. did with several drugmakers.

  • The EU, meanwhile, is exporting around 40% of the doses it produces, with the U.K. receiving the most.
Expand chart

What to watch: Brussels’ emphasis on “equitable distribution” is fading amid a brutally slow rollout and rising case counts.

  • Not only are export bans under consideration, but European Commission President Ursula von der Leyen said Sunday that plans to donate doses to poorer countries are on hold until the EU’s domestic picture improves.

The supply shortfalls in Europe have led to a debate over another somewhat controversial vaccine: Russia's Sputnik V.

  • Why it matters: The latest data suggests the vaccine is safe and highly effective, and Russia wants to sell it all over the world — particularly within the EU. Several member states want to buy it, and some are prepared to help produce it.
  • German Chancellor Angela Merkel said she'd be willing to go it alone to order Sputnik V if approved by regulators even if there was no common European decision on using it.

The big picture: Having an effective state-funded vaccine could be a diplomatic coup for Moscow, but Russia lags behind the other major players in terms of manufacturing capacity and so is working to cut production deals around the world.

What they're saying: “We have absolutely no need of Sputnik V,” Thierry Breton, the head of the EU's vaccine task force said on Sunday.

  • He argued that the bloc was on pace to have sufficient capacity by the end of June using EU-made vaccines — likely long before enough Sputnik V would be available to make a meaningful difference.
  • The other side: The vaccine's developers called Breton "clearly biased against the Sputnik V vaccine just because it is Russian,” adding, “Biases lead to failures. And Breton’s failures are clear to many people in EU."

The latest: Meanwhile in Slovakia, Prime Minister Igor Matovic has said he's prepared to resign after announcing the purchase of Sputnik doses without the backing of his coalition partners.

Go deeper: Biden's vaccine diplomacy challenge.

Go deeper

Updated 18 mins ago - Politics & Policy

Prosecutor to seek hate crime charges, death penalty in Atlanta shootings

In Hopkinton, Mass., the Rally & Run To Stop Asian Hate is held to show solidarity in the wake of deadly Atlanta shootings and to mourn the loss of eight lives including six Asian women. Photo: Jonathan Wiggs/The Boston Globe via Getty Images

Prosecutors unveiled murder charges against the white man accused of shooting and killing eight people, six of whom were Asian women, at Atlanta-area spas, AP reports.

Driving the news: A prosecutor filed notice that she plans to seek hate crime charges and the death penalty in the case. Two separate grand juries have now indicted the suspect on murder charges.

America's pandemic coin crunch returns

Illustration: Sarah Grillo/Axios

An early pandemic problem that plagued businesses is back: not enough change to go around.

Why it matters: The pandemic broke America's coin flow. It has repercussions for millions that rely on it for daily transactions.